by In2Pharma | Feb 12, 2024 | News
The Netherlands Koag Kag/Keuringsraad has published the data for their basic training on the codes for promotion towards general public regarding medicinal products, medical devices and health products. This training takes place in Breukelen, The Netherlands, at...
by In2Pharma | Feb 11, 2024 | News
Luxembourg On January 17th, EMA published the newest version (v28) of QRD Appendix V. In this version, the contact details for reporting adverse drug reactions in Luxemburg has been changed, to include the German version of the address. Luxembourg/Luxemburg [French]...
by In2Pharma | Feb 10, 2024 | News
The Netherlands Via the MEB website, a planning tool is already available to reserve a timeslot for requesting assessment procedures for decentralized procedures. The planning tool helps the MEB to properly plan the required capacity. This tool has now been expanded...
by In2Pharma | Dec 29, 2023 | News
Belgium Since 03 December 2023, a new royal decree has been published regarding the reporting of adverse reactions related to the use of food supplements. This Royal Decree defines the legal framework for Nutrivigilance, but not its mode of operation in...
by In2Pharma | Dec 29, 2023 | News
Belgium An update of the Royal Decree of 7 April 1995 on information and advertising for medicines for human use was published to include the degree of “Master in pharmaceutical sciences” as an acceptable degree to obtain the RIP recognition: Source: Royal Decree of 7...
by In2Pharma | Dec 29, 2023 | News
The Netherlands As previously announced, the Foundation for the Code for Pharmaceutical Advertising (“the CGR”) and the Foundation for the Code of Conduct for Medical Devices (“the GMH”) have decided to further tighten their rules as of January 1st, 2024....
